Aliskiren
- Generic Name
- Aliskiren
- Brand Names
- Rasilez, Tekturna, Tekturna Hct
- Drug Type
- Small Molecule
- Chemical Formula
- C30H53N3O6
- CAS Number
- 173334-57-1
- Unique Ingredient Identifier
- 502FWN4Q32
- Background
Aliskiren is the first drug in the renin inhibitor drug class and is used for the treatment of hypertension. It was developed by Speedel and Novartis and initially approved by the FDA in early 2007. Aliskiren has been proven to efficacious in reducing blood pressure when used alone or in conjunction with other antihypertensive agents.
- Indication
Aliskiren is used for the treatment of hypertension in children above 6 years and adults. This drug may also be used in conjunction with antihypertensives such as calcium channel blockers and thiazides in products form to provide additional blood pressure control.
- Associated Conditions
- Hypertension
Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2008-10-03
- Last Posted Date
- 2011-05-09
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1191
- Registration Number
- NCT00765674
- Locations
- 🇹🇷
Investigative Site, Ankara, Turkey
Blood Pressure Lowering of Aliskiren HCTZ Compared to HCTZ in Stage 2 Systolic Hypertension in Older Population
- First Posted Date
- 2008-09-26
- Last Posted Date
- 2011-04-04
- Lead Sponsor
- Novartis
- Target Recruit Count
- 451
- Registration Number
- NCT00760266
- Locations
- 🇺🇸
Sites in USA, East Hanover, New Jersey, United States
Blood Pressure Lowering of Aliskiren Hydrochlorothiazide (HCTZ) Versus Amlodipine in Stage 2 Hypertension in African Americans
- Conditions
- Hypertension
- First Posted Date
- 2008-08-22
- Last Posted Date
- 2016-10-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 332
- Registration Number
- NCT00739596
- Locations
- 🇺🇸
Sites in USA, East Hanover, New Jersey, United States
Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension
- Conditions
- Hypertension
- Interventions
- Drug: PlaceboDrug: Aliskiren/amlodipine 150/10 mg tabletDrug: Aliskiren/amlodipine 300/5 mg tabletDrug: Aliskiren/amlodipine 150/5 mg tabletDrug: Aliskiren/amlodipine 300/10 mg tablet
- First Posted Date
- 2008-08-22
- Last Posted Date
- 2011-06-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 2694
- Registration Number
- NCT00739973
- Locations
- 🇦🇺
Invesigative Site, Canberra, Australia
🇨🇳Investigative Site, Taipei, Taiwan
Aliskiren's Effect on Arterial Stiffness and Platelet Function in Patients With Diabetes Mellitus (DM)
- First Posted Date
- 2008-08-12
- Last Posted Date
- 2008-08-12
- Lead Sponsor
- Assaf-Harofeh Medical Center
- Target Recruit Count
- 40
- Registration Number
- NCT00732407
Aliskiren and Muscle Sympathetic Nerve Activity
- Conditions
- Chronic Kidney DiseaseHypertensionMuscle Sympathetic Nerve Activity
- Interventions
- First Posted Date
- 2008-07-21
- Last Posted Date
- 2010-01-14
- Lead Sponsor
- UMC Utrecht
- Target Recruit Count
- 30
- Registration Number
- NCT00719316
- Locations
- 🇳🇱
University Medical Center utrecht, Utrecht, Netherlands
Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Elderly Patients With Essential Hypertension When Given With a Light Meal in a 8 Week Placebo-controlled Study
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2008-06-27
- Last Posted Date
- 2011-06-28
- Lead Sponsor
- Novartis
- Target Recruit Count
- 756
- Registration Number
- NCT00706134
- Locations
- 🇸🇰
Investigative Site, Bratislava, Slovakia
Efficacy and Safety of the Combination Aliskiren (300 mg) and Hydrochlorothiazide (25mg) to Aliskiren (300mg) Monotherapy in Patients With Staged II Hypertension
- Conditions
- Hypertension
- Interventions
- Drug: Aliskiren/hydrochlorothiazide (HCTZ) (300/25 mg)
- First Posted Date
- 2008-06-26
- Last Posted Date
- 2011-05-30
- Lead Sponsor
- Novartis
- Target Recruit Count
- 688
- Registration Number
- NCT00705575
- Locations
- 🇹🇷
Investigative Site, Ankara, Turkey
A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential Hypertension
- Conditions
- Essential Hypertension
- Interventions
- First Posted Date
- 2008-04-28
- Last Posted Date
- 2021-06-07
- Lead Sponsor
- Novartis
- Target Recruit Count
- 564
- Registration Number
- NCT00667719
- Locations
- 🇹🇷
Investigative Site, Turkey, Turkey
A Clinical Study to Evaluate Renal Hemodynamic Responses to Aliskiren in Patients With Type 2 Diabetes Mellitus
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2008-04-17
- Last Posted Date
- 2012-08-29
- Lead Sponsor
- Novartis
- Target Recruit Count
- 45
- Registration Number
- NCT00660309
- Locations
- 🇺🇸
Novartis Investigator Site, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.